Antibody immunosuppressive therapy in solid-organ transplant: Part I
- PMID: 20150766
- PMCID: PMC2840233
- DOI: 10.4161/mabs.2.2.11159
Antibody immunosuppressive therapy in solid-organ transplant: Part I
Abstract
Currently, a wide variety of both polyclonal and monoclonal antibodies are being routinely utilized to prevent and treat solid organ rejection. More commonly, these agents are also administered in order to delay introduction of calcineurin inhibitors, especially in patients with already compromised renal function. While these antibody therapies dramatically reduced the incidence of acute rejection episodes and improved both short and long-term graft survival, they are also associated with an increased incidence of opportunistic infections and neoplastic complications. Therefore, effective patient management must necessarily balance these risks against the potential benefits of the therapy.
Figures
References
-
- Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med. 1963;268:1315–1323. - PubMed
-
- Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet. 1979;8151:1033–1036. - PubMed
-
- Norman D, Turka L. Primer on Transplantation. Wiley Blackwell; 2001.
-
- Collins WA, Humphreys RM, Davis MB, Ibele WE, Dworkin M, Kinsey J, et al. The Crime of Saving Lives: The FDA, John Najarian and Minnesota ALG. Arch Surg. 1996;131:451–452. - PubMed
-
- Wechter WJ, Brodie JA, Morrell RM, Rafi M, Schultz JR. Antithymocyte Globulin (ATGAM) in renal allograft recipients. Multicenter trials using a 14-dose regimen. Transplantation. 1979;28:294–302. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical